Pathology software and services provider, Deciphex, has raised €3.9m in fresh funding.

It brings to €14.4m the total investment raised by the company in its Series B round.

The money is being provided by Seroba Life Sciences and some of the firm's existing investors.

The business said it would use the fresh injection of capital to continue the development and rollout of its products and services.

It will also further expand its presence in the UK, Canada, the Middle East and the US.

"This additional investment will allow us to continue to grow and innovate, solidifying our position as a leader in the field of pathology," said Donal O'Shea, CEO of Deciphex.

"We are committed to helping pathologists deliver the best possible care to patients through the use of cutting-edge technology."

Deciphex claims that with longer life expectancy and increasing populations, the need for high-quality reliable diagnosis is rising, but capacity in pathology services can’t keep pace.

As a result, it says, there is a need for innovative solutions to help maintain high standards in patient care.

The company has developed a range of services including a platform for research pathology and a remote subspecialty pathology service.

It says demand for its services has risen four-fold over recent quarters.

"Deciphex is at the forefront of the digital pathology and AI revolution, and we are excited to be supporting the company as it continues to grow and expand," said Jennifer McMahon, partner at Seroba.

"We believe that Deciphex's innovative solutions will have a significant impact on the field of pathology, improving diagnostic quality and productivity."